Squarepoint
INBX icon

Squarepoint’s Inhibrx INBX Stock Holding History

Squarepoint’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05M Buy
15,639
+12,241
+360% +$908K ﹤0.01% 2738
2025
Q4 		$268K Buy
+3,398
New +$232K ﹤0.01% 3685
2024
Q4 		– Sell
-21,066
Closed -$330K – 5246
2024
Q3 		$330K Buy
+21,066
New +$296K ﹤0.01% 3385

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Squarepoint's INBX Position: Q1 2026 in Review

Squarepoint increased its Inhibrx (INBX) stake by 360% in Q1 2026, buying an estimated $908K and bringing the position to 15,639 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2738.

Squarepoint first reported a position in INBX in Q3 2024 and has held it in 3 quarters since. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Squarepoint held 15,639 shares of Inhibrx worth $1.05M as of Q1 2026.
  • Squarepoint bought 12,241 Inhibrx shares in Q1 2026, an estimated $908K.
  • Inhibrx made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2738 holding.
  • Squarepoint first reported a position in Inhibrx in Q3 2024 and has held it in 3 quarters since.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.